A new trial update on vosoritide was recorded on September 9, 2026. The study, titled "Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia," is registered under identifier NCT07073014. It is listed as a Phase 3 trial. Its current status is enrolling by invitation, meaning participation is limited to previously identified or eligible participants rather than open public enrollment.
This trial update does not include any efficacy or safety results. It reflects only the trial's registration status, phase, and enrollment stage as of the listed date. No outcome data, interim findings, or conclusions about the treatment's effects in children with hypochondroplasia have been reported as part of this update.
Vosoritide is currently an approved compound. This long-term extension study is designed to continue observation of participants in a Phase 3 setting. Further details about study design, participant criteria, and timelines are available through the official clinical trial registry listing.
Readers interested in general background on this compound can consult the vosoritide overview for additional context.